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Introduction
In 2006, 429 900 cases of breast cancer were diag-
nosed in Europe (the most frequent malignant tumour,
13.5% of all cancers), and the respective mortality
reached 131 900 cases [1]. In 2008, in turn, 182 460
cases of breast cancer were detected in the United
States, with the mortality of 40 480 cases. In parallel
with pulmonary cancer and colorectal carcinoma, this
was one of the three most frequent malignant tumours,
accounting together for, around, 50% of neoplastic dis-
eases in USA, representing the most frequent cause of
death of women 20 to 59 years of age [2]. In view of
the above, an early diagnosis and effective treatment of
disease are immensely important. Intensive studies are
being carried out on determining reliable prognostic
factors of a high specificity and sensitivity which
could increase efficiency of treatment in such cases.
Markers of a significant prognostic value manifest 
a strict correlation between intensity of their expression
and prognosis. In clinical practice cases frequently
occur, which manifest similar pathological characters
but differ from each other in the course of the disease
and in sensitivity to the applied treatment procedures.
While evaluation of Ki-67 antigen expression is com-
mon in prognostic analysis of various tumour types
(including soft tissue tumours, breast cancers, lung or
prostate, brain tumours), examination of MCM-2 pro-
tein expression in such tumours, including breast can-
cer, still remains in its preliminary phase [4,7]. 
Ki-67 belongs to the group of most frequently
estimated proliferation markers but its value as 
a prognostic marker has not been sufficiently proven
and studies which dealt with the relationship between
cell proliferation and clinical course of a disease fre-
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quently yielded divergent results [3-8]. During inter-
phase Ki-67 co-localizes with perinuclear located DNA
and DNA located near the nuclear envelope what sug-
gests that it is involved in perinuclear chromatin organ-
ization [9]. Expression of Ki-67 may develop also in
situations of an inhibited DNA synthesis or when the
cell undergoes the process of apoptosis [10]. Since both
biological functions of Ki-67 and its significance as a
prognostic factor remain unclear, it has been decided to
include into the prognostic routine another proliferation
marker, the MCM-2 protein. Until today, its estimation
has been restricted exclusively to investigative purpos-
es and it has not been applied in clinical and patholog-
ical evaluations. Its indubitable advantage includes the
fact that biology of the factor is well recognized.
MCM-2 belongs to the family of MCM (minichromo-
some maintenance) proteins, which includes the
homogenous group of six proteins (MCM-2 to 7),
responsible for the start and maintenance of replication
[11-12]. At the early G1 phase of the cell cycle, MCM
proteins are responsible for formation of the pre-repli-
cation complex, what differs them from the Ki-67 anti-
gen, which is mostly present in late G1, S, G2 stages of
the cell cycle [14,15]. The contained in the complex
MCM proteins manifest activity of helicase, which dis-
entangles DNA threads during replication process [15].
In the course of replication, this provides an appropri-
ate access to all regions of DNA. At the S phase of the
cell cycle MCM proteins irreversibly bind to the chro-
matin, which warrants that exactly one genetic materi-
al replication event occurs per a single cell division
[16-17]. In view of the above, expression of MCM
family proteins, including MCM-2 proteins, may in
future be contemplated to be used as a new prolifera-
tion marker since its expression is elevated in rapidly
dividing cells [18-20]. This study attempted to examine
correlation between expressions of MCM-2 protein and
Ki-67 proliferation antigen and to compare their
expression in ductal breast cancers of different histo-
logical malignancy grades (G).
Material and methods
Patients. The studies were performed on 56 archival paraffin
blocks containing fragments of invasive ductal breast cancers,
sampled in 2002 during procedures of mammectomy in the Lower
Silesia Oncology Centre in Wroclaw. Age of the patients ranged
from 35 to 83 years (the mean of 54.93±10.87 SD years), all the
patients were of female sex. The histological malignancy grade (G)
was determined using guidelines suggested by WHO [21]. The
clinical and pathological data were obtained from archives of the
Lower Silesia Oncology Centre in Wroclaw (Table 1).
Immunohistochemistry. Tissue samples were fixed in 10%
buffered formalin, dehydratated and embedded in paraffin. In each
case, hematoxylin and eosin-stained preparations were subjected to
histopathological evaluation by two pathologists. Formalin-fixed,
paraffin-embedded tissue was freshly cut (4 μm). The paraffin sec-
tions were mounted on Superfrost slides (Menzel Gläser, Ger-
many), dewaxed with xylene and gradually re-hydrated. Activity of
endogenous peroxidase was blocked by 30 min exposure to 1%
H2O2. The IHC reactions were performed using monoclonal anti-
bodies against MCM-2, originating from Novocastra (clone
CRCT2.1, 1:50, Novocastra Laboratories Ltd, Balliol Bussiness
Park West, Benton Lane, Newcastle upon Tyne, NE12 8EW, UK)
and against Ki-67 antibody, originating from Dako (clone MIB-1,
1:50, Dako, Denmark A/S, Produktionsvej 42, DK-2600 Glostrup,
Denmark). The antibody was diluted in antibody diluent with the
background reducing component. All the reactions were accompa-
nied by the respective control reactions in which specific antibod-
ies were substituted by the Universal Negative Control for N-series
Mouse Primary Antibodies Kit, N1698 (Dako). The studied paraf-
fin sections were boiled in the Antigen Retrieval Solution in
microwave oven in order to unblock antigenic determinants. The
investigated antigens were visualized using biotinylated antibod-
ies, streptavidin-biotinylated peroxidase complex (LSAB, Dako)
and diaminobenzidine (DAB, Dako). All the sections were coun-
terstained with Meyer's hematoxylin (20 second). 
Evaluation of the intensity of IHC reaction. The intensity of Ki-
67 antigen and MCM-2 protein expression was evaluated using
computer-assisted image analysis. In every section three fields were
selected with the highest number of tumour cells yielding positive
reaction /Hot Spots/. Percentage of positive cells in Hot Spots was
evaluated scoring the brown-labelled cells nuclei, detected after
screening of all cell nuclei under ×400 magnification (Olympus 
BX-42 light microscope with the visual mode AnalySis 3.2 software
for computer-assisted image analysis). The general result for every
sample was an average of the three hot spot percentages. The intensi-
ty of the IHC reactions was independently evaluated in coded prepa-
rations by two pathologists (AW, CK); in doubtful cases a re-evalua-
tion was performed using a double-headed microscope and the stain-
ing was discussed until a consensus was achieved. The examining
pathologists knew no clinical details related to the respective patient.  
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Table 1. Clinical and pathological characteristic of studied
patients. 
Statistical analysis. The results were subjected to statistical analysis
using Statistica 7.1 PL software (Statsoft, Poland). The relationship
between the expression of Ki-67 antigen and MCM-2 protein was
examined using Spearman's rank correlation. The relationship
between expression intensity of the two proteins and histological
malignancy grade G was examined using ANOVA rank test of
Kruskal-Wallis. The differences were accepted as significant at
p<0.05.
Results
All the examined tumours manifested nuclear expres-
sion of Ki-67 antigen (Fig. 1A) and MCM-2 protein
(Fig. 1B). In hematoxylin-counterstained serial sec-
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Fig. 2. Correlation of Ki-67 antigen expression with MCM-2 pro-
tein expression in ductal breast cancer: r=0.6; p<0.05. 
Fig. 3. Intensity of Ki-67 antigen expression *p<0.001 G3 vs. G1
and G2 (A) and of MCM-2 protein: *p<0.05 G3 vs. G1 and G2 
(B) in ductal breast cancers. 
Fig. 4. Comparison between expression of Ki-67 antigen and that
of MCM-2 protein in ductal breast cancers manifesting various
grades of histological malignancy G; *p<0.05 G2: Ki-67 vs. MCM-
2.
Fig. 1. Nuclear expression of Ki-67 (A) and MCM-2 protein (B) in
ductal breast cancer. Serial sections, counterstaining with haema-
toxylin (original magnification ×100).
tions intensely brown-stained cell nuclei were noted.
Statistical analysis of the relationship between expres-
sion of the two markers Ki-67 and MCM-2 demon-
strated a strong positive correlation between expres-
sions of the two markers (r=0.6; p<0.05) (Fig. 2). Also
the relationship was examined between expression of
the examined proteins and G grade of studied tumours.
A more pronounced expression of Ki-67 antigen was
demonstrated in G3 than that in G1 or G2 (p<0.001)
(Fig. 3A) and, in the case of MCM-2 protein in G3
than that in G1 (p<0.05) or G2 (p<0.01) (Fig. 3B). For
either marker the difference between expression in G1
and G2 proved to be insignificant. Also, expressions of
Ki-67 antigen and MCM-2 protein were compared
between individual grades of histological malignancy
(G) of the studied tumours. Only in tumours of G2
grade expression of Ki-67 antigen was significantly
lower than expression of MCM-2 protein (Fig. 4). In
the case of Ki-67 antigen the average of 11% tumour
cells manifested its expression in G1, 10% in G2 and
18% in G3 while in the case of MCM-2 protein the
mean percentage of positive tumour cells amounted to
17% in G1, 13% in G2 and 30% in G3.
Discussion
Expression of Ki-67 and MCM-2 markers and rela-
tionships between the two were examined in relatively
numerous studies. Expression of the proteins was stud-
ied in cancers of the larynx, oral cavity, thyroid gland,
in tumours of salivary gland, colorectal cancers,
tumours of adrenal glands, lungs and in renal carcino-
ma [22-31,33]. Results of some investigators suggest-
ed a higher prognostic value of MCM-2 protein than
that manifested by currently widely used Ki-67
[23,28,30,34,35].
Chatrath et al. [22] examined benign and malignant
lesions in the larynx. Their statistical analysis demon-
strated a very strong correlation between expression of
Ki-67 and that of MCM-2, which pointed to a similar
prognostic value of the studied proteins. Szelachowska
et al. [23] studied spinocellular cancers of oral cavity
and demonstrated a higher prognostic value of MCM-
2 as compared to that of Ki-67. In the cases of thyroid
tumours, Mehrorta et al. [24] observed increased
expression of both markers in malignant lesions (fol-
licular and papillary tumours). The studies demon-
strated also that neither MCM-2 nor Ki-67 could be
applied for distinguishing benign from malignant
lesions in the thyroid gland. Giaginis et al. (25)
showed that expression of MCM-2 was significantly
linked to clinical and pathological data and manifested
strong correlation with cell proliferation in colon car-
cinoma. In turn, studies of Guziñska-Ustymowicz et
al. [26] on colorectal cancers demonstrated that an
increase in MCM-2 expression might point to devel-
opment of metastases to lymph nodes. In other studies
Vargas et al. [27] showed in tumours of salivary glands
that MCM-2 was a strong marker of differentiation
between benign and malignant lesions. Szajerka et
al.[28] compared expression of MT, Ki-67 and MCM-2
in tumours of adrenal cortex. They demonstrated a very
strong correlation between MCM-2 and MT and a mod-
erate correlation between MCM-2 and Ki-67. In view of
their results MCM-2 seems to provide a reliable indica-
tor of malignant processes in adrenal cortex. In cases of
pulmonary adenocarcinomas Hashimoto et al. [29]
demonstrated a similar diagnostic usefulness of both Ki-
67 and MCM-2. On the other hand, Yang et al. [30] sug-
gested that in non-small cell lung carcinomas two mark-
ers in parallel, MCM-2 and gesoline should be estimat-
ed. In such tumour the authors found that usage of Ki-
67 manifested no prognostic value. In renal carcinoma,
in turn, Dudderidge et al. [31] suggested that MCM-2
should be used as a marker of proliferation and progno-
sis. Moreover, Kodani et al. [32] suggested that an
increased expression of MCM-2 and p53 may point to a
malignant neoplastic transformation in cells of oral
mucosa. They tried to explain it that the MCM-2 expres-
sion could involve the p53 protein-dependent pathway
and, in parallel, they found that MCM-2 represents a
useful marker of proliferation. 
Expression of MCM-2 protein was already studied
in some papers concerning breast cancer. Reena et al.
[34] examined MCM-2 expression in benign and
malignant lesions of the breast. Similarly to us, they
noted a high MCM-2 proliferation index in tumours
manifesting grade G3 of histological malignancy and a
relatively low index in tumours of G1 grade, pointing
to positive correlation between MCM-2 expression
and G grade. Gonzales et al.[35] obtained very similar
results in studies on breast cancers, indicating that
expression of MCM-2 was a more frequent and more
pronounced than those of the widely used Ki-67. They
postulated that MCM-2 labelling index represents a
strong independent prognostic factor and for a more
reliable prognostic evaluation it should be considered
in parallel with parameters of the Nottingham Prog-
nostic Index (NPI). Ki-67 and MCM-2 were also eval-
uated in advanced gastric cancer. Although this study
did not show any correlation between both markers,
shorter postoperative survival time was associated
with high MCM-2 expression [33].
Results of our studies have demonstrated an
increased nuclear expression of both MCM-2 protein
and Ki-67 antigen in ductal breast cancers. Results
obtained by us and other authors comparing expression
of the two proteins point to a comparable value of the
two markers, sometimes suggesting a higher signifi-
cance of MCM-2. Ki-67 antigens represents the widely
used proliferation marker in mammary gland cancers
but there is lack of explanation related to the mecha-
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nisms in which the protein acts suggest a search for
other prognostic factors. The difference in expression
of both markers between G1 and G2 grades was
insignificant. In view of the strong correlation in
expression of the studied markers the potential of a
more frequent determination of MCM-2 antigen could
be considered, as a marker of proliferation in breast
malignant tumours. This may be particularly valuable
in ductal breast cancers since expression of the protein
correlates with its G malignancy grade.
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